Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

The 50,000-square-foot dedicated state-of-the-art CGT facility represents the next milestone in BBIL's long-standing mission to deliver targeted, life-saving treatments that address unmet clinical ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

Current treatments are mainly hormones and broad-spectrum immunosuppressants, but these can lead to a decline in the patient’s immunity. Chimeric antigen receptor T (CAR-T) Cell therapy has emerged, ...

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...